Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRADFORD A BRABEC

Allopathic & Osteopathic Physicians Pediatrics

NPI
1700863826
CMS profile
213505
Location
LINCOLN, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,944.37

16 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,148.43 4
Food and Beverage $795.94 12

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRADFORD A BRABEC

NPI 1700863826 · CMS profile ID 213505

Allopathic & Osteopathic Physicians / Pediatrics

LINCOLN, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700863826?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRADFORD A BRABEC, NPI 1700863826, CMS profile ID 213505. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700863826?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BRADFORD A BRABEC, NPI 1700863826, CMS profile ID 213505. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700863826?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BRADFORD A BRABEC, NPI 1700863826, CMS profile ID 213505, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1700863826?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

16 matching records · $1,944.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 16 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–16 of 16.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ironshore Pharmaceuticals Inc. $18.2709/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707541421 CMS
PFIZER INC. $97.9709/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673655393 CMS
Merck Sharp & Dohme Corporation $3.6509/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695892701 CMS
GlaxoSmithKline, LLC. $13.0508/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671210305 CMS
Ironshore Pharmaceuticals Inc. $16.5708/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707559737 CMS
PFIZER INC. $11.6108/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673276167 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.3207/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681944979 CMS
PFIZER INC. $130.4307/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673629529 CMS
PFIZER INC. $654.7107/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673629531 CMS
PFIZER INC. $467.2207/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673629533 CMS
PFIZER INC. $452.8107/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673629535 CMS
JAZZ PHARMACEUTICALS INC. $11.4604/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684172163 CMS
Sobi, Inc $19.7103/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698090089 CMS
Vertical Pharmaceuticals, LLC $11.2203/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675495349 CMS
PFIZER INC. $11.2002/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673236899 CMS
PFIZER INC. $9.1701/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673769059 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,944.37 16
PY2020 $26.17 2
PY2021 $78.22 6
PY2022 $28.87 2
PY2023 $357.26 8
PY2024 $992.59 2
PY2025 $25.70 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $186,978.56 17
PY2024 Principal investigator $95,383.48 11
PY2023 Recipient $28,195.18 4
PY2023 Principal investigator $164,446.72 32
PY2022 Principal investigator $356,062.23 46
PY2021 Principal investigator $527,634.01 76
PY2020 Principal investigator $306,669.77 74
PY2019 Principal investigator $67,433.90 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

74 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $4,865.00 12/16/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 742877309
Principal investigator 1 PFIZER INC. $7,418.75 12/15/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742894497
Principal investigator 1 PFIZER INC. $1,583.40 12/11/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742867025
Principal investigator 1 PFIZER INC. $208.00 12/11/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742867335
Principal investigator 1 PFIZER INC. $950.04 12/02/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742866545
Principal investigator 1 PFIZER INC. $124.80 12/02/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742867023
Principal investigator 1 PFIZER INC. $13,917.07 12/02/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742893425
Principal investigator 1 PFIZER INC. $1,156.25 12/02/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 742894499
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 11/24/2020 Non-covered Recipient Entity
Midwest Childrens Health Research
MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalen No dispute reported 06/30/2026 744020246
Principal investigator 1 SANOFI PASTEUR INC. $1,100.00 11/24/2020 Non-covered Recipient Entity
Midwest Childrens Health Research
MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalen No dispute reported 06/30/2026 744020257
Principal investigator 1 PFIZER INC. $11,136.34 11/20/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860459
Principal investigator 1 PFIZER INC. $72.80 11/17/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742866947
Principal investigator 1 PFIZER INC. $554.19 11/17/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742867019
Principal investigator 1 PFIZER INC. $656.25 11/17/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 742874925
Principal investigator 1 PFIZER INC. $1,406.25 11/17/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 742909115
Principal investigator 1 PFIZER INC. $156.00 11/02/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742866549
Principal investigator 1 PFIZER INC. $1,187.55 11/02/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742867015
Principal investigator 1 PFIZER INC. $21,959.56 10/28/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860463
Principal investigator 1 PFIZER INC. $124.80 10/26/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742866543
Principal investigator 1 PFIZER INC. $950.04 10/26/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742867333
Principal investigator 1 PFIZER INC. $11,752.12 10/16/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860227
Principal investigator 1 PFIZER INC. $6,605.00 10/16/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 742874251
Principal investigator 1 PFIZER INC. $870.87 10/12/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742867325
Principal investigator 1 PFIZER INC. $114.40 10/12/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742867329
Principal investigator 1 SANOFI PASTEUR INC. $3,634.00 10/08/2020 Non-covered Recipient Entity
Midwest Childrens Health Research
MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalen No dispute reported 06/30/2026 744020127
Principal investigator 1 PFIZER INC. $13,286.34 10/01/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860223
Principal investigator 1 PFIZER INC. $72.80 09/30/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860469
Principal investigator 1 PFIZER INC. $554.19 09/30/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860697
Principal investigator 1 PFIZER INC. $3,302.50 09/30/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 742874249
Principal investigator 1 PFIZER INC. $633.36 09/21/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860915
Principal investigator 1 PFIZER INC. $83.20 09/21/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860919
Principal investigator 1 PFIZER INC. $48,824.44 09/17/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860457
Principal investigator 1 PFIZER INC. $1,029.21 09/14/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860683
Principal investigator 1 PFIZER INC. $135.20 09/14/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860691
Principal investigator 1 PFIZER INC. $633.36 09/02/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860687
Principal investigator 1 PFIZER INC. $83.20 09/02/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860909
Principal investigator 1 PFIZER INC. $62.40 08/24/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860453
Principal investigator 1 PFIZER INC. $475.02 08/24/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860911
Principal investigator 1 PFIZER INC. $791.70 08/18/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860699
Principal investigator 1 PFIZER INC. $104.00 08/18/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742861137
Principal investigator 1 PFIZER INC. $316.68 08/10/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860467
Principal investigator 1 PFIZER INC. $41.60 08/10/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860705
Principal investigator 1 PFIZER INC. $9,536.85 08/07/2020 Non-covered Recipient Entity
MW Childrens Health Res Inst
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949010731
Principal investigator 1 PFIZER INC. $3,645.00 08/05/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 742907937
Principal investigator 1 PFIZER INC. $52.00 08/03/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860693
Principal investigator 1 PFIZER INC. $395.85 08/03/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860903
Principal investigator 1 PFIZER INC. $475.02 07/21/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860701
Principal investigator 1 PFIZER INC. $62.40 07/21/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742860905
Principal investigator 1 PFIZER INC. $5,500.00 06/30/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742861357
Principal investigator 1 PFIZER INC. $83.20 06/15/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742861133
Principal investigator 1 PFIZER INC. $633.36 06/15/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742861359
Principal investigator 1 PFIZER INC. $62.40 05/28/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742861127
Principal investigator 1 PFIZER INC. $475.02 05/28/2020 Non-covered Recipient Entity
Midwest Childrens Health
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742861129
Principal investigator 1 SANOFI PASTEUR INC. $701.35 05/26/2020 Non-covered Recipient Entity
Midwest Childrens Health Research
MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalen No dispute reported 06/30/2026 744020013
Principal investigator 1 PFIZER INC. $1,520.00 05/21/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 742910511
Principal investigator 1 PFIZER INC. $16,500.00 05/09/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 742878711
Principal investigator 1 Merck Sharp & Dohme Corporation $97.05 05/05/2020 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 740742709
Principal investigator 1 PFIZER INC. $1,062.50 05/01/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 742907437
Principal investigator 1 PFIZER INC. $5,428.50 04/22/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 742911359
Principal investigator 1 Merck Sharp & Dohme Corporation $609.00 04/16/2020 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 740742465
Principal investigator 1 SANOFI PASTEUR INC. $68,379.00 04/16/2020 Non-covered Recipient Entity
Midwest Childrens Health Research
MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalen No dispute reported 06/30/2026 744019969
Principal investigator 1 PFIZER INC. $11,773.21 04/11/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 742908563
Principal investigator 1 Merck Sharp & Dohme Corporation $48.33 03/20/2020 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 740706333
Principal investigator 1 Merck Sharp & Dohme Corporation $77.31 03/20/2020 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 740706421
Principal investigator 1 Merck Sharp & Dohme Corporation $77.67 03/20/2020 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 740706423
Principal investigator 1 Merck Sharp & Dohme Corporation $85.02 03/20/2020 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 740706427
Principal investigator 1 Allergan, Inc. $194.50 03/17/2020 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH I
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, Ages 7 to 17 Years, With Irritable Bowel Syndrome With Constipation (IBS-C) No dispute reported 06/30/2026 721265275
Principal investigator 1 PFIZER INC. $1,177.50 03/07/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 742907487
Principal investigator 1 PFIZER INC. $2,125.00 02/27/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 742909677
Principal investigator 1 PFIZER INC. $1,062.50 02/22/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 742906969
Principal investigator 1 PFIZER INC. $5,082.50 01/31/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 742908021
Principal investigator 1 Merck Sharp & Dohme Corporation $148.80 01/28/2020 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 740706387
Principal investigator 1 PFIZER INC. $1,031.25 01/21/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 742908539
Principal investigator 1 PFIZER INC. $4,635.00 01/07/2020 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 742909213